Brands
Discover
Events
Newsletter
More

Follow Us

twitterfacebookinstagramyoutube
Youtstory

Brands

Resources

Stories

General

In-Depth

Announcement

Reports

News

Funding

Startup Sectors

Women in tech

Sportstech

Agritech

E-Commerce

Education

Lifestyle

Entertainment

Art & Culture

Travel & Leisure

Curtain Raiser

Wine and Food

YSTV

ADVERTISEMENT
Advertise with us

Nephro Care India IPO subscribed nearly 716 times

The kidney care provider intends to utilise Rs 26.17 crore of the IPO proceeds for setting-up a multi-speciality healthcare facility, Vivacity Multi Speciality Hospital, at Madhyamgram near Kolkata, while the remaining capital will be used for general corporate purposes.

Nephro Care India IPO subscribed nearly 716 times

Wednesday July 03, 2024 , 2 min Read

The initial public offering (IPO) of Nephro Care India was subscribed 715.85 times on Tuesday, helped by heavy participation from institutional investors.

The Rs 41.26-crore initial share sale received bids for 2,23,00,38,400 shares against 31,15,200 shares on offer.

The portion for non-institutional investors received 1,787.56 times subscription; the quota for retail individual investors was subscribed 634.12 times, as per NSE data.

Additionally, the quota for qualified institutional buyers received 245.14 times subscription, and employee portion was subscribed 20.44 times, bringing the overall subscription to 715.85 times.

The Kolkata-headquartered healthcare provider said on Friday that it raised Rs 11.14 crore from anchor investors.

The IPO comprises fresh issuance of 45.84 lakh equity shares.

Shares were available for public subscription in the range of Rs 85-90 per scrip.

The kidney care provider intends to utilise Rs 26.17 crore of the IPO proceeds for setting-up a multi-speciality healthcare facility, Vivacity Multi Speciality Hospital, at Madhyamgram near Kolkata, while the remaining capital will be used for general corporate purposes.

The new hospital is proposed to include 100 in-patient beds, including a 30-bed critical care unit. It will offer treatment services in various disciplines such as cardiology, medical oncology, gastroenterology, and gynaecology, and also includes an advanced renal transplant unit in East India.

In December 2023, Nephro Care India closed the pre-IPO funding round, which saw the participation of banking veteran and former chairman of HDFC Ltd Deepak Parekh, chairman of HDFC Securities Bharat Shah, and Founder and MD of Macleods Pharmaceuticals Rajendra Agarwal, among others.

Nephro Care India posted a revenue of Rs 19.75 crore and earned a profit (PAT) of Rs 3.4 crore during the first nine months of FY24.

The shares of the company will be listed on the NSE Emerge platform.

Corporate Capital Ventures is the book running lead manager, and Bigshare Services is the registrar for the issue.


Edited by Swetha Kannan